Isa Odidi

Dr. Isa Odidi, Ph.D., is a Founder and one of the Principals of IntelliPharmaCeutics, and serves as Chairman of the board, Chief Executive Officer, Co-Chief Scientific Officer and Chair of the scientific advisory board. From 1995 to 1998, Dr. Odidi served as the Director and subsequent Vice President of Research, Drug Development and New Technologies at Biovail Corporation International (now Biovail Corporation), a drug delivery company. During this time, he developed several blockbuster drugs, including supergenerics of the very-difficult-to-duplicate Adalat CC (Bayer) and Procardia XL (Pfizer). Prior to 1995, Dr. Odidi held senior positions in academia, and in the pharmaceutical and health care industries. He currently holds a Chair as Professor of Pharmaceutical Technology at the Toronto Institute of Pharmaceutical Technology in Canada, and he is an Adjunct Professor at the Institute for Molecular Medicine in California. Dr. Odidi received his B.Sc. degree in pharmacy from Ahmadu Bello University, and his M.Sc. in pharmaceutical technology and Ph.D in pharmaceutics from the University of London, England. He is a graduate of the Western Executive Management Program at the Ivey School of Business, University of Western Ontario, and he obtained his MBA from the prestigious Rotman School of Business at the University of Toronto. Dr. Odidi’s work has been cited in textbooks, and he has published over a hundred scientific and medical papers, articles and textbooks.